Skip to content
DataLookout
Menu

NCT07885761

REVIVE-FR Registry

StatusWithdrawn
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below.

  1. Stopped Withdrawn before enrolling Sponsor's reason: Sponsor Change
    • Enrollment target: estimated 200 to confirmed 0
  2. Study First Submitted
  • Stopped: terminated, suspended or withdrawn

Endpoints

Primary

REVIVE-FR Success at 30 Days
Timeframe: 30 days after procedure
Early Safety at 30 Days
Timeframe: 30 days after procedure

Secondary (6)

Clinical Outcomes at 1 Year
Valve Durability at 1 Year
All-Cause and Cardiovascular Mortality in the Medical-Management Cohort
Heart Failure Hospitalization in the Medical-Management Cohort
Unplanned Aortic Valve Reintervention in the Medical-Management Cohort
Show 1 moreShow less
Echocardiographic Progression of Transcatheter Heart Valve Failure

Arms and interventions

TAVI-in-SAVR (ViV) patients

transfemoral THV implantation into a failed surgical bioprosthesis, any VARC-3 failure mechanism.

THV-in-THV (redo-TAVI)

transfemoral THV implantation into a failed THV, SVD-driven failure (VARC-3 Stage II/III)

Explant-TAVR

surgical explantation of a failed THV, enrolled directly within REVIVE-FR (not as an external comparator)

Medical Management

failing THV due to SVD or endocarditis, managed conservatively (i.e., without TAVI-in-SAVR, THV-in-THV, or surgical explantation); a descriptive, real-world reference cohort, not powered for statistical comparison with the interventional cohorts

Procedures: TAVI-in-SAVR (Valve-in-Valve), THV-in-THV (Redo-TAVI), Surgical Explantation of a Failed Transcatheter Heart Valve

Other: Medical management